These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17956151)

  • 21. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.
    Edwards SJ; Smith CJ
    Clin Ther; 2009 Jun; 31 Pt 1():1345-59. PubMed ID: 19698898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic issues in patients with severe mental illness.
    Citrome L; Blonde L; Damatarca C
    South Med J; 2005 Jul; 98(7):714-20. PubMed ID: 16108240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine - relapse prevention following mania.
    Dando S; Tohen M
    J Psychopharmacol; 2006 Mar; 20(2 Suppl):31-8. PubMed ID: 16551670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight gain due to long term antipsychotic treatment of persistent mental disorders.
    Tadger S; Melamed Y
    Psychiatr Danub; 2008 Mar; 20(1):37-41. PubMed ID: 18376329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.
    Karagianis J; Hoffmann VP; Arranz B; Treuer T; Maguire GA; de Haan L; Chawla B
    Hum Psychopharmacol; 2008 Jun; 23(4):275-81. PubMed ID: 18338426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
    Gao J; Li J; Lu X; Yang J
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.
    Ketter TA; Haupt DW
    Curr Med Res Opin; 2006 Dec; 22(12):2345-53. PubMed ID: 17257449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine: review of safety 2008.
    Kantrowitz JT; Citrome L
    Expert Opin Drug Saf; 2008 Nov; 7(6):761-9. PubMed ID: 18983222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotics: newer options for mania and maintenance therapy.
    Vieta E; Goikolea JM
    Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weight gain with atypical antipsychotics: evidence and insights.
    Henderson DC
    J Clin Psychiatry; 2007; 68 Suppl 12():18-26. PubMed ID: 17956152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of bipolar disorder with antipsychotic medication: issues shared with schizophrenia.
    Young AH
    J Clin Psychiatry; 2007; 68 Suppl 6():24-5. PubMed ID: 17650056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
    Dilla T; Prieto L; Ciudad A; Sacristán JA
    Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of atypical antipsychotics in children: balancing safety and effectiveness.
    Kohlstadt I; Vitiello B
    Am Fam Physician; 2010 Mar; 81(5):585. PubMed ID: 20187594
    [No Abstract]   [Full Text] [Related]  

  • 36. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine-fluoxetine combination for the treatment of bipolar depression.
    Citrome L
    Expert Opin Pharmacother; 2011 Dec; 12(17):2751-8. PubMed ID: 22035291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects.
    Srivastava S; Ketter TA
    Clin Ther; 2011 Dec; 33(12):B40-8. PubMed ID: 22177379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Olanzapine].
    Wittköpper K; El-Armouche A; Eschenhagen T
    Dtsch Med Wochenschr; 2008 Sep; 133(39):1958-62. PubMed ID: 18798132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.